Vanguard Group Inc. Acquires 365,959 Shares of Savara Inc (NASDAQ:SVRA)

Vanguard Group Inc. lifted its holdings in shares of Savara Inc (NASDAQ:SVRA - Free Report) by 4.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,309,970 shares of the company's stock after buying an additional 365,959 shares during the quarter. Vanguard Group Inc. owned about 4.84% of Savara worth $25,512,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Rosalind Advisors Inc. bought a new position in Savara in the 4th quarter worth about $8,151,000. State Street Corp lifted its holdings in shares of Savara by 15.7% in the third quarter. State Street Corp now owns 4,138,276 shares of the company's stock worth $17,546,000 after buying an additional 560,242 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Savara by 10.8% in the third quarter. Geode Capital Management LLC now owns 2,726,850 shares of the company's stock valued at $11,564,000 after acquiring an additional 264,825 shares during the period. Raymond James Financial Inc. purchased a new position in Savara during the fourth quarter valued at approximately $798,000. Finally, Barclays PLC increased its holdings in Savara by 217.5% during the 3rd quarter. Barclays PLC now owns 231,005 shares of the company's stock worth $979,000 after acquiring an additional 158,244 shares during the period. 87.93% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on the stock. HC Wainwright reissued a "buy" rating and issued a $6.00 price target on shares of Savara in a report on Friday, March 28th. Wells Fargo & Company assumed coverage on Savara in a research note on Friday, December 20th. They set an "overweight" rating and a $8.00 price objective for the company. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, Savara currently has a consensus rating of "Moderate Buy" and a consensus target price of $8.83.

Savara Price Performance

SVRA stock traded up $0.08 during midday trading on Friday, reaching $3.01. The company had a trading volume of 465,408 shares, compared to its average volume of 1,317,363. The firm has a 50-day moving average price of $2.74 and a 200-day moving average price of $3.09. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The company has a market capitalization of $519.63 million, a P/E ratio of -7.00 and a beta of 0.52. Savara Inc has a 1 year low of $2.26 and a 1 year high of $5.31.

Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). The business had revenue of $0.27 million during the quarter. On average, research analysts anticipate that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.